NCT03406000 - Phase 4 Study to Evaluate Treatment Optimization With Once-daily Insulin Glargine 300 U/mL | Biotech Hunter

Enrollment

170

Participants

Timeline

Start Date

January 22, 2018

Primary Completion Date

February 4, 2019

Study Completion Date

February 4, 2019

Conditions

Type I Diabetes Mellitus

Interventions

DRUG

INSULIN GLARGINE (U300)

"Pharmaceutical form: Solution for Injection~Route of administration: Subcutaneous injection"

Trial Locations (11)

Investigational Site Number 076011, Ribeirão Preto

Investigational Site Number 076013, Campinas

Investigational Site Number 076016, Curitiba

Investigational Site Number 076007, Curitiba

Investigational Site Number 076005, Fortaleza

Investigational Site Number 076001, São Paulo

Investigational Site Number 076002, Goiânia

Investigational Site Number 076004, Porto Alegre

Investigational Site Number 076006, São José dos Campos

Investigational Site Number 076015, São Paulo

Investigational Site Number 076012, São Paulo